The American Association for Cancer Research (AACR) conference held in Orlando, Florida, was an exceptional platform for our pre-clinical research organization (CRO) to showcase groundbreaking research and forge invaluable connections within the global oncology community. We are excited to share our experience of meeting existing and potential clients at the event and explore the innovation happening at LIDE based on the research we presented. Namely, the application of MiniPDX® in clinical indication identification and anti-tumor drug development, as well as the evaluation of novel immuno-oncology drugs using humanized immune cells and cancer co-inoculated models were poster presentations that generated further interest in Lide Biotech.
Engaging Potential Clients:
The AACR conference proved to be an ideal setting to engage with potential clients from various sectors of the oncology community. Our CRO's presence and the relevance of our research drew significant attention. Numerous industry leaders, clinicians, researchers, and pharmaceutical representatives expressed keen interest in our work, initiating fruitful discussions and exploring potential collaborations. These interactions have opened doors to exciting opportunities, allowing us to establish solid connections and expand our client base. We were fortunate that our CEO, Dr. Danyi Wen was able to attend the event and was on-site for the presentation of both of our posters.
Application of MiniPDX® in Clinical Indication Identification and Anti-Tumor Drug Development:
DOWNLOAD POSTER HERE
Our first research topic, the application of MiniPDX® in clinical indication identification and anti-tumor drug development, received widespread acclaim at the conference. MiniPDX®, our proprietary technology, allows for the generation of patient-derived xenograft (PDX) models on a smaller scale, offering a more efficient and cost-effective approach. Using these models, we can accurately replicate the patient's tumor microenvironment and evaluate the efficacy of potential anti-tumor drugs with higher precision.
The research showcased the successful application of MiniPDX® in identifying optimal clinical indications for specific drug candidates. By analyzing the response of MiniPDX® models to different therapies, we demonstrated our ability to predict clinical outcomes and personalize treatment strategies. These findings resonated strongly with industry professionals, pharmaceutical companies, and clinicians, fostering a promising outlook for collaboration in optimizing drug development pipelines and advancing precision medicine.
Novel Immuno-Oncology Drugs Evaluation by Humanized Immune Cells and Cancer Co-Inoculated Models:
DOWNLOAD POSTER HERE
Our second research topic, evaluating novel immuno-oncology drugs using humanized immune cells and cancer-co-inoculated models, sparked significant interest and excitement among conference attendees. Immuno-oncology has emerged as a groundbreaking field, revolutionizing cancer treatment by harnessing the immune system's power. Our research presented a novel approach that employed humanized immune cells and co-inoculated models, allowing for accurate evaluation of the efficacy and safety of new immuno-oncology drugs.
By utilizing these advanced models, we demonstrated enhanced prediction of treatment response, identification of potential adverse effects, and evaluation of combination therapies. This breakthrough research provided tangible evidence of the immense potential of immuno-oncology drugs and our CRO's ability to drive innovation in this field. The presented findings attracted the attention of leading pharmaceutical companies, clinical researchers, and academic institutions, fostering collaborations that will shape the future of cancer treatment.
The Future of Our Company:
The success we experienced at the AACR conference, both in terms of engaging potential clients and the impact of our research, has set the stage for an exciting future for our company. The connections forged at the conference will likely lead to collaborative partnerships with industry leaders, enabling us to expand our service offerings and drive innovation in clinical research.
The application of MiniPDX® and our pioneering approach to immuno-oncology drug evaluation have positioned us as a frontrunner in the field. As precision medicine gains prominence and immuno-oncology continues transforming cancer treatment, our CRO is poised to play a pivotal role.
LIDE delivers innovations in oncology translational research and immuno-oncology. Contact Global Vice President, Josh Caggiula today to learn more about our first-class research capabilities.